Abstract 24TiP
Background
A high-risk subpopulation of ER+/HER2− breast cancer (BC) is characterized by high-grade tumors, decreased sensitivity to endocrine therapy (ET), higher responsiveness to chemotherapy (CT), and worse prognosis. Prior studies suggest that increased pathological complete response (pCR) rates after neoadjuvant CT may have a substantial impact for patients with high-risk, early-stage, HR+/HER2− BC. KEYNOTE-756 (NCT03725059) is a global, randomized, double-blind, phase 3 study of pembrolizumab (vs placebo) + CT as neoadjuvant treatment followed by pembrolizumab (vs placebo) + ET as adjuvant treatment for patients with high-risk, early-stage, ER+/HER2− BC.
Trial design
Patients with T1c-2 cN1-2 (tumor size ≥2 cm) or T3-4 cN0-2 grade 3, invasive, ductal ER+/HER2− BC will be stratified by lymph node involvement (positive vs negative), tumor PD-L1 status (positive [CPS ≥1] vs negative [CPS <1]), ER positivity (ER + ≥10% vs ER + <10%), and anthracycline dosing schedule (every 3 weeks [Q3W] vs Q2W), then randomized 1:1 to neoadjuvant treatment with pembrolizumab 200 mg Q3W or placebo combined with paclitaxel (80 mg/m2 Q1W) for 4 cycles followed by doxorubicin (60 mg/m2) or epirubicin (100 mg/m2), each with cyclophosphamide (600 mg/m2) Q2/3W for 4 cycles. After definitive surgery (± radiation therapy, as indicated), patients will receive adjuvant treatment of pembrolizumab (200 mg Q3W) or placebo for 9 more administrations combined with ET, which can be given for up to 10 years. No crossover between treatment cohorts when moving from neoadjuvant to adjuvant treatment is allowed. Dual primary endpoints are pCR rate (ypT0/Tis ypN0) and event-free survival (EFS). Secondary endpoints include ypT0/Tis and ypT0 ypN0 pCR rates in all patients and all 3 pCR definitions in those with PD-L1+ tumors, EFS in patients with PD-L1+ tumors, overall survival, safety, and health-related quality of life. Enrollment is currently ongoing in 22 countries around the world, including Korea, Taiwan, China, and Japan.
Clinical trial identification
NCT03725059.
Legal entity responsible for the study
Merck & Co., Inc.
Funding
Funding for this study was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Disclosure
F. Cardoso: Advisory / Consultancy: Amgen; Advisory / Consultancy: Astellas/Medivation; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Celgene; Advisory / Consultancy: Daiichi-Sankyo; Advisory / Consultancy: Eisai; Advisory / Consultancy: GE Oncology; Advisory / Consultancy: Genentech; Advisory / Consultancy: GlaxoSmithKline; Advisory / Consultancy: Macrogenics; Advisory / Consultancy: Medscape; Advisory / Consultancy: Merck-Sharp; Advisory / Consultancy: Merus BV; Advisory / Consultancy: Mylan; Advisory / Consultancy: Mundipharma GmbH; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Pierre-Fabre; Advisory / Consultancy: prIME Oncology; Advisory / Consultancy: Roche. A. Bardia: Advisory / Consultancy, Research grant / Funding (self): bioTheranostics; Advisory / Consultancy: Genentech; Advisory / Consultancy: Genentech/Roche; Advisory / Consultancy: Immunomedics; Advisory / Consultancy: Innocrin Pharmaceuticals; Advisory / Consultancy: Merck; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Radius Health; Advisory / Consultancy: Radius Pharma; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Spectrum Pharmaceuticals. F. André: Research grant / Funding (institution): Novartis; Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Roche. D.W. Cescon: Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Pfizer; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Genomic Health; Advisory / Consultancy, Research grant / Funding (institution): GlaxoSmithKline; Advisory / Consultancy, Research grant / Funding (institution): Merck; Research grant / Funding (institution): Roche/Genentech. H. McArthur: Advisory / Consultancy: Celgene; Advisory / Consultancy, Research grant / Funding (self): Merck; Advisory / Consultancy: OBI Pharma; Advisory / Consultancy: Roche; Advisory / Consultancy: Spectrum Pharmaceuticals; Advisory / Consultancy: Syndax Pharmaceuticals; Advisory / Consultancy: Peregrine; Advisory / Consultancy: Calithera; Research grant / Funding (self): Bristol-Myers Squibb; Research grant / Funding (self): Eli Lilly; Research grant / Funding (self): MedImmunne; Research grant / Funding (self): LLC/AstraZeneca. M. Telli: Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy, Research grant / Funding (institution): Genentech; Advisory / Consultancy: Aduro; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy: Immunomedics; Advisory / Consultancy: Celldex; Advisory / Consultancy, Research grant / Funding (institution): Tesaro; Research grant / Funding (institution): OncoSec; Research grant / Funding (institution): Biothera; Research grant / Funding (institution): Vertex; Research grant / Funding (institution): Calithera; Research grant / Funding (institution): Merck Serono; Research grant / Funding (institution): PharmaMar. S. Loi: Advisory / Consultancy: AstraZeneca/MedImmune; Advisory / Consultancy, Research grant / Funding (institution): Bristol-Myers Squibb; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy: Pfizer; Advisory / Consultancy, Research grant / Funding (institution): Roche/Genentech; Advisory / Consultancy: Seattle Genetics; Research grant / Funding (institution): Lilly; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Puma Biotechnology. J. Cortes: Shareholder / Stockholder / Stock options: MedSIR; Honoraria (self), Travel / Accommodation / Expenses: Novartis; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Eisai; Honoraria (self), Advisory / Consultancy: Celgene; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Pfizer; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Honoraria (self): Samsung; Advisory / Consultancy: Cellestia Biotech; Advisory / Consultancy, Research grant / Funding (institution): AstaZeneca; Advisory / Consultancy: Biothera; Advisory / Consultancy: Merus; Advisory / Consultancy: Seattle Genetics; Advisory / Consultancy: Daiichi-Sankyo; Advisory / Consultancy: ERYTECH Pharma; Advisory / Consultancy: Polyphor; Research grant / Funding (institution): ARIAD; Research grant / Funding (institution): Baxalta GmbH; Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Guardant Health; Research grant / Funding (institution): Merck. P. Schmid: Full / Part-time employment: Roche; Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self): Bayer; Honoraria (self): Boehringer Ingelheim; Honoraria (self): Celgene; Honoraria (self): Eisai; Honoraria (self), Research grant / Funding (institution): Genentech/Roche; Honoraria (self), Research grant / Funding (institution): Merck; Honoraria (self), Research grant / Funding (institution): Novartis; Honoraria (self): Pfizer; Honoraria (self): Puma Biotechnology; Research grant / Funding (institution): Astellas Pharma; Research grant / Funding (institution): Medivation; Research grant / Funding (institution): Oncogenex. N. Harbeck: Honoraria (self), Advisory / Consultancy: Lilly; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Pfizer. C. Denkert: Honoraria (self), Advisory / Consultancy: Amgen; Honoraria (self): Novartis; Honoraria (self): Pfizer; Honoraria (self): Teva; Honoraria (self): Roche; Shareholder / Stockholder / Stock options: Sividon Diagnostics; Advisory / Consultancy: Daiichi-Sankyo; Advisory / Consultancy: MSD Oncology; Licensing / Royalties, patent application—therapy response: EP20150702464; Licensing / Royalties, patent application— cancer immunotherapy: EP18209672; Licensing / Royalties, digital pathology software: VMScope. C. Jackisch: Honoraria (self), Advisory / Consultancy: Merck. L. Jia: Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck. K. Hirshfield: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck. V. Karantza: Shareholder / Stockholder / Stock options, Full / Part-time employment: Merck.
Resources from the same session
397P - Development of prediction model for hepatocellular carcinoma in chronic hepatitis B patients
Presenter: Teerapat Ungtrakul
Session: Poster display session
Resources:
Abstract
398P - Planning for future cancer control programs in Uganda: Projections of top five cancers’ incidence in the next decade
Presenter: Judith Asasira
Session: Poster display session
Resources:
Abstract
399P - Prevalence of colorectal cancer risk factors in apparently healthy adults in Suluhan Village, Bali
Presenter: Cindy Trisina
Session: Poster display session
Resources:
Abstract
400P - Female lung cancer: Emerging issue in Bangladesh
Presenter: Muhammad Rafiqul Islam
Session: Poster display session
Resources:
Abstract
402P - Work-related outcomes among cancer survivors in Singapore
Presenter: Chia Jie Tan
Session: Poster display session
Resources:
Abstract
407P - Focal treatments for metastatic soft tissue sarcoma (mSTS) is associated with improved overall survival
Presenter: Ching Tso Chen
Session: Poster display session
Resources:
Abstract
408P - The Asian sarcoma consortium sarcoma preceptorship program: A program evaluation study utilizing the Kirkpatrick model (Level 1 and 2)
Presenter: Fernando Gracieux Jr.
Session: Poster display session
Resources:
Abstract
409P - Integrated genomic and transcriptomic analysis revealed mutagenic patterns of dedifferentiated liposarcoma and leiomyosarcoma in Chinese patients
Presenter: Yuhong Zhou
Session: Poster display session
Resources:
Abstract
410P - Treatment patterns and outcomes of elderly patients with metastatic soft tissue sarcomas (mSTS)
Presenter: Yu-ju Kuo
Session: Poster display session
Resources:
Abstract
411P - Comparative analysis of protein profiles of prognosis-associated proteins and KIT-related proteins in gastrointestinal stromal tumour
Presenter: Yoshiyuki Suehara
Session: Poster display session
Resources:
Abstract